---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-25-000104"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:11:38.281931+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M

## Summary
- Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.
- Adjusted EPS $0.12 vs $0.05 YoY; adjusted EBITDA $9.3M vs $5.6M; gross margin 74.2% up from 73.8%.
- Raised FY25 revenue guidance to at least 17% growth, or $219M; reiterates gross margin 73-75% and net cash flow positive.
- FDA accepted BLA for Avance Nerve Graft; PDUFA date Sept 5, 2025; pre-licensing inspection and regulatory milestones completed.

## SEC filing metadata
- accession: 0000805928-25-000104
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592825000104/0000805928-25-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592825000104/axgn-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-25-000104
- JSON: https://secwatch.observer/filing/0000805928-25-000104.json
- Plain text: https://secwatch.observer/filing/0000805928-25-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.